DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how ...

Quarter four revenue was $2,112.5 million. Full year revenue was $8,251 million. Quarter four adjusted EBITDA of $327.1 million or 15.5% of revenue; full year adjusted ...

Net business wins in the quarter of $2,328 million. Reflects a net book to bill in the quarter of 1.15, and a trailing twelve month net book to bill of 1.21. Closing backlog of $24.3 billion, an ...

Quarter one revenue of $2,034.0 million, an increase of 0.9% on quarter one 2025. Quarter one adjusted EBITDA of $317.7 million or 15.6% of revenue. GAAP net income for the quarter of $104.8 million ...

Icon (NASDAQ:ICLR) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga ...

Quarter one revenue of $2,034.0 million, an increase of 0.9% on quarter one 2025. Quarter one adjusted EBITDA of $317.7 ...

Stock-based compensation expense represents the amount of recurring expense related to the company’s equity compensation programs (inclusive of employer related taxes). (b) Foreign currency ...

DUBLIN--(BUSINESS WIRE)-- ICON plc (ICLR) (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today reported its financial results for the first quarter ...

Stock-based compensation expense represents the amount of expense related to the Company’s equity compensation programs (inclusive of employer related taxes). The articles, information, and content ...

Stock-based compensation expense represents the amount of recurring expense related to the company’s equity compensation programs (inclusive of employer related taxes). (b) Foreign currency ...